JSPR investors face $50M+ lawsuit deadline - here's what you need to know
Key Points
- Jasper Therapeutics faces a class action lawsuit for alleged...
When a biotech company gets sued for allegedly fibbing about manufacturing compliance, it's like finding out your chef has been lying about washing their hands. The food might taste fine, but suddenly you're questioning everything on the menu.
Jasper Therapeutics (NASDAQ: JSPR) is serving up exactly this kind of investor indigestion. The Rosen Law Firm filed a class action lawsuit on September 27, covering investors who bought shares between November 30, 2023, and July 3, 2025. The allegations? Jasper supposedly made false statements about following Good Manufacturing Practices (cGMP) and the...
While we have taken every measure to build an AI pipeline that generates credible and accuracte news, we still encourage you to conduct your own research before making investment decisions. InsAIght's content should not be considered professional financial or trading advice.